Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, Leyssen P, Neyts J, Jochmans D. · 2022

Read Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. by Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, Leyssen P, Neyts J, Jochmans D. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8785409.txt.

Description

Vangeel and co-authors test whether three antiviral drugs stay active against Omicron and other variants of concern. The drugs were remdesivir, molnupiravir, and nirmatrelvir, plus their parent compounds. Tests ran in infected cells treated with a range of doses. The ancestral virus and all five variants of concern were covered.

All compounds blocked each virus at near equal strength. Their targets, the viral copying enzyme and its main protease, change little across variants. That matches the flat results seen in the assays. The authors conclude these drugs should keep working as variants shift. The finding supports their use while vaccines face immune escape.

Catalog record

CREATORVangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, Leyssen P, Neyts J, Jochmans D.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE17 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8785409

Browse the full library · About the Tower of Babel